Home / Biotechnology / Liquid Biopsy Market by Product & Service (Reagents, Instruments, and Service), Cancer Type (Lung, Breast, Colorectal, Prostate, Liver, and Others), Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA [CtDNA], and Other Biomarkers) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Liquid Biopsy Market by Product & Service (Reagents, Instruments, and Service), Cancer Type (Lung, Breast, Colorectal, Prostate, Liver, and Others), Circulating Biomarker (Circulating Tumor Cells, Extracellular Vesicles, Circulating Tumor DNA [CtDNA], and Other Biomarkers) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Published: May 2017 | No Of Pages: 164 | Published By: Allied Market Research

Global Liquid Biopsy Market was valued at $634 million in 2016, and is estimated to reach at $3,805 million by 2023, registering a CAGR of 28.9% from 2017 to 2023. Liquid biopsy tests are executed to understand the molecular aspects of cancer across the healthcare and research settings, such as hospitals, physicians, pathological and research laboratories. It is a non-invasive blood test that could provide researchers, physicians, and surgeons with information about the cancer profile of the patient and appropriate therapy to improve the survival rate of the cancer patients. It is a rapid process that usually includes a simple blood draw, extraction of nucleic acids from the blood plasma, and amplification of the molecular targets to permit analysis of the defined biomarkers. Easy and non-invasive access to the tumor genome, early cancer diagnosis & detection, characterization of new lesions, drug & therapeutic target identifications for cancer treatment are some advantages of liquid biopsies, which improve the safety and efficiency of cancer therapy for patients. The advantages of liquid biopsy over solid tumor biopsy, rise in awareness about minimally invasive procedures, favorable government initiatives, and presence of huge cancer population base are major factors that drive the market growth.

The global liquid biopsy market is segmented based on product & service, circulating biomarker, cancer type, end user, and geography. Based on product & service, it is categorized into reagents, instruments and services. On the basis of circulating biomarker, it is classified into circulating tumor cells, circulating tumor DNA, extracellular vesicles and other biomarkers. The market is studied across different cancer types, such as lung, breast, colorectal, prostate, liver, and other cancers. Based on end user, it is bifurcated into hospitals & laboratories and government & academic research centers. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The market is expected to witness a moderate growth during the forecast period, owing to the benefits offered by liquid biopsies over solid tissue biopsy methods. Furthermore, surge in prevalence of cancer and rise in awareness about minimally invasive methods among the patient pool are anticipated to augment the market growth. The increase in pre-screening programs for cancer detection is expected to present various opportunities for market expansion. However, alternatives to liquid biopsies and unclear reimbursement & regulation scenario are expected to hamper the market growth.

The report provides extensive competitive analysis and profiles of key market players, such as Biocept, Inc., Qiagen, F. Hoffmann-La Roche AG, Bio-Rad Laboratories Inc., Myriad Genetics, Janssen Diagnostics, LLC., Trovagene Inc., Guardant Health Inc., GRAIL, and MDX Health SA.

The other players in the value chain include Fraunhofer-Gesellschaft, Horizon Discovery, Illumina, Inc., Cynvenio, Diagnologix, Exosome Sciences, and CyoTrack.

Asia-Pacific possesses high market potential for the growth of liquid biopsy market, owing to high incidence of cancer and rise in healthcare expenditure. This region is anticipated to experience fast-paced growth, in terms of development and use of liquid biopsy tests.

India liquid biopsy market is projected to grow at a CAGR of 32.7% during the forecast period.

Key Benefits

This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
Market estimations are based on comprehensive analysis of the key developments in the industry.
In-depth analysis based on geography assists to understand the regional market and the strategic business planning.
The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

Liquid Biopsy Market Key Segments

By Product & Service

Reagents
Instruments
Services

By Cancer Type

Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Other Cancers

By Circulating Biomarker

Circulating Tumor Cells
Extracellular Vesicles
Circulating Tumor DNA
Other Biomarkers

By End User

Hospitals & Laboratories
Government & Academic Research Centers

By Geography

North AmericaU.S.
Canada
Mexico
EuropeGermany
France
UK
Italy
Spain
Rest of Europe
Asia-PacificJapan
China
Australia
India
South Korea
Taiwan
Rest of Asia-Pacific
LAMEABrazil
Turkey
Saudi Arabia
South Africa
Rest of LAMEA

Chapter: 1 INTRODUCTION
1.1. REPORT DESCRIPTION

1.2. KEY BENEFITS

1.3. KEY MARKET SEGMENTS

1.4. RESEARCH METHODOLOGY
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE

3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. TOP PLAYER POSITIONING, 2016

3.4. PORTERS FIVE FORCES ANALYSIS

3.5. REGULATIONS

3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.1.1. Increase in demand for safe and non-invasive procedures
3.6.1.2. Surge in prevalence of cancer worldwide.
3.6.1.3. Advantages of liquid biopsy tests
3.6.2. Restraints
3.6.2.1. Limitations associated with liquid biopsy testing
3.6.2.2. Lack of awareness in developing in underdeveloped regions
3.6.3. Opportunities
3.6.3.1. Rise in pre-screening programs for cancer detection using liquid biopsy
3.6.3.2. Untapped potential of emerging markets

Chapter: 4 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE
4.1. OVERVIEW
4.1.1. Market size and forecast

4.2. KITS & REAGENTS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. PLATFORMS & INSTRUMENTS
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. SERVICES
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

Chapter: 5 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER
5.1. OVERVIEW
5.1.1. Market size and forecast

5.2. CIRCULATING TUMOR CELL (CTC)
5.2.1. Market size and forecast

5.3. CIRCULATING TUMOR DNA (CTDNA)
5.3.1. Market size and forecast

5.4. EXTRACELLULAR VESICLES (EVS)
5.4.1. Market size and forecast

5.5. OTHER BIOMARKERS
5.5.1. Market size and forecast

Chapter: 6 LIQUID BIOPSY MARKET, BY CANCER TYPE
6.1. OVERVIEW
6.1.1. Market Size and Forecast

6.2. LUNG CANCER
6.2.1. Market size and forecast

6.3. BREAST CANCER
6.3.1. Market size and forecast

6.4. COLORECTAL CANCER
6.4.1. Market size and forecast

6.5. PROSTATE CANCER
6.5.1. Market size and forecast

6.6. LIVER CANCER
6.6.1. Market size and forecast

6.7. OTHER CANCERS
6.7.1. Market size and forecast

Chapter: 7 LIQUID BIOPSY MARKET, BY END USER
7.1. OVERVIEW
7.1.1. Market size and forecast

7.2. HOSPITAL AND LABORATORY
7.2.1. Market size and forecast

7.3. GOVERNMENT AND ACADEMIC RESEARCH CENTERS
7.3.1. Market size and forecast

Chapter: 8 LIQUID BIOPSY MARKET, BY GEOGRAPHY
8.1. OVERVIEW
8.1.1. Market size and forecast

8.2. NORTH AMERICA
8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast
8.2.3.1. U.S. market size and forecast
8.2.3.2. Canada market size and forecast
8.2.3.3. Mexico market size and forecast

8.3. EUROPE
8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast
8.3.3.1. Germany market size and forecast
8.3.3.2. France market size and forecast
8.3.3.3. UK market size and forecast
8.3.3.4. Italy market size and forecast
8.3.3.5. Rest of Europe market size and forecast

8.4. ASIA-PACIFIC
8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast
8.4.3.1. Japan market size and forecast
8.4.3.2. China market size and forecast
8.4.3.3. Australia market size and forecast
8.4.3.4. India market size and forecast
8.4.3.5. South Korea market size and forecast
8.4.3.6. Taiwan market size and forecast
8.4.3.7. India market size and forecast
8.4.3.8. Rest of Asia-Pacific market size and forecast

8.5. LAMEA
8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast
8.5.3.1. Brazil market size and forecast
8.5.3.2. Turkey market size and forecast
8.5.3.3. Saudi Arabia market size and forecast
8.5.3.4. South Africa market size and forecast
8.5.3.5. Rest of LAMEA market size and forecast

Chapter: 9 COMPANY PROFILES
9.1. BIOCEPT, INC.
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance

9.2. QIAGEN N.V.
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Product portfolio
9.2.5. Business performance

9.3. F. HOFFMANN-LA ROCHE AG
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance

9.4. BIO-RAD LABORATORIES INC.
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Product portfolio
9.4.5. Business performance

9.5. MYRIAD GENETICS
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance

9.6. JANSSEN DIAGNOSTICS, LLC.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Product portfolio
9.6.5. Business performance

9.7. TROVAGENE INC.
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance

9.8. GUARDIANT HEALTH, INC.
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance

9.9. GRAIL
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance

9.10. MDX HEALTH SA
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Product portfolio
9.10.5. Business performance

TABLE 1. GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2016-2023 ($MILLION)
TABLE 2. KITS & REAGENTS BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 3. PLATFORMS & INSTRUMENTS LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 4. SERVICE LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 5. GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2016-2023 ($MILLION)
TABLE 6. CTC LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 7. CTDNA LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 8. EVS LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 9. OTHER BIOMARKERS LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 10. GLOBAL LIQUID BIOPSY MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 11. LUNG CANCER LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 12. BREAST CANCER LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 13. COLORECTAL CANCER LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 14. PROSTATE CANCER LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 15. LIQUID BIOPSY LIVER CANCER MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 16. LIQUID BIOPSY OTHER CANCERS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 17. GLOBAL LIQUID BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 18. HOSPITAL AND LABORATORY LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 19. GOVERNMENT AND ACADEMIC RESEARCH CENTER LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 20. LIQUID BIOPSY MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 21. NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 22. NORTH AMERICA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2016-2023 ($MILLION)
TABLE 23. NORTH AMERICA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2016-2023 ($MILLION)
TABLE 24. NORTH AMERICA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2016-2023 ($MILLION)
TABLE 25. NORTH AMERICA LIQUID BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 26. EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27. EUROPE LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2016-2023 ($MILLION)
TABLE 28. EUROPE LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2016-2023 ($MILLION)
TABLE 29. EUROPE LIQUID BIOPSY MARKET, BY CANCER TYPE, 2016-2023 ($MILLION)
TABLE 30. EUROPE LIQUID BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 31. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 32. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2016-2023 ($MILLION)
TABLE 33. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2016-2023 ($MILLION)
TABLE 34. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CANCER TYPE, 2016-2023 ($MILLION)
TABLE 35. ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 36. LAMEA LIQUID BIOPSY MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 37. LAMEA LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2016-2023 ($MILLION)
TABLE 38. LAMEA LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2016-2023 ($MILLION)
TABLE 39. LAMEA LIQUID BIOPSY MARKET, BY CANCER TYPE, 2016-2023 ($MILLION)
TABLE 40. LAMEA LIQUID BIOPSY MARKET, BY END USER, 2016-2023 ($MILLION)
TABLE 41. BIOCEPT, INC.:COMPANY SNAPSHOT
TABLE 42. QIAGEN N.V.:COMPANY SNAPSHOT
TABLE 43. F. HOFFMANN-LA ROCHE AG:COMPANY SNAPSHOT
TABLE 44. BIO-RAD LABORATORIES INC.:COMPANY SNAPSHOT
TABLE 45. MYRIAD GENETICS:COMPANY SNAPSHOT
TABLE 46. JANSSEN DIAGNOSTICS, LLC:COMPANY SNAPSHOT
TABLE 47. TROVAGENE, INC.:COMPANY SNAPSHOT
TABLE 48. GUARDANT HEALTH, INC.:COMPANY SNAPSHOT
TABLE 49. GRAIL:COMPANY SNAPSHOT
TABLE 50. MDX HEALTH SA:COMPANY SNAPSHOT

FIGURE 1. GLOBAL LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS IN GLOBAL LIQUID BIOPSY MARKET
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE AND DISTRIBUTION
FIGURE 4. TOP WINNING STRATEGIES: TYPE AND COMPANY
FIGURE 5. TOP WINNING STRATEGIES: TYPE AND NATURE
FIGURE 6. BARGAINING POWER OF BUYERS
FIGURE 7. BARGAINING POWER OF SUPPLIERS
FIGURE 8. THREAT OF NEW ENTRANTS
FIGURE 9. THREAT OF SUBSTITUTION
FIGURE 10. COMPETITIVE RIVALRY
FIGURE 11. GLOBAL LIQUID BIOPSY MARKET: CIRCULATING BIOMARKER SEGMENTATION
FIGURE 12. U.S. LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 13. CANADA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 14. MEXICO LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 15. GERMANY LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 16. FRANCE LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 17. UK LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 18. ITALY LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 19. REST OF EUROPE LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 20. JAPAN LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 21. CHINA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 22. AUSTRALIA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 23. INDIA ONCOLOGY LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 24. SOUTH KOREA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 25. TAIWAN LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 26. INDIA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 27. REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 28. BRAZIL LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 29. TURKEY LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 30. SAUDI ARABIA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 31. SOUTH AFRICA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)
FIGURE 32. REST OF LAMEA LIQUID BIOPSY MARKET, 2016-2023 ($MILLION)

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +